4
H index
0
i10 index
42
Citations
Katharina Elisabeth Blankart : Citation Profile
Universität Hamburg (5% share) | RESEARCH PRODUCTION: 17 Articles 4 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
11 years (2011 - 2022). Relations with other researchers
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Katharina Elisabeth Blankart. | Is cited by:
| Cites to:
|
Main data
Where Katharina Elisabeth Blankart has published?
| Journals with more than one article published | # docs |
|---|---|
| Health Policy | 6 |
| The European Journal of Health Economics | 3 |
| IJERPH | 2 |
| Medical Decision Making | 2 |
Recent works citing Katharina Elisabeth Blankart (2024 and 2023)
| Year | Title of citing document |
|---|---|
| 2023 | Quantity versus quality in publication activity: knowledge production at the regional level. (2023). Peker, Irina ; Gareev, Timur. In: Papers. RePEc:arx:papers:2311.08830. Full description at Econpapers || Download paper |
| 2023 | Market diffusion of biosimilars in off-patent biologic drug markets across Europe. (2023). Steiner, Isa Maria ; Bohm, Anna-Katharina ; Stargardt, Tom. In: Health Policy. RePEc:eee:hepoli:v:132:y:2023:i:c:s0168851023001033. Full description at Econpapers || Download paper |
| 2023 | Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms: cross-country evidence from weighted-average least squares estimation. (2022). Czypionka, Thomas ; Rohrling, Gerald ; Reiss, Miriam ; Pock, Markus ; Berger, Michael. In: LSE Research Online Documents on Economics. RePEc:ehl:lserod:116928. Full description at Econpapers || Download paper |
| 2023 | Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms. (2023). Czypionka, Thomas ; Rohrling, Gerald ; Reiss, Miriam ; Pock, Markus ; Berger, Michael. In: International Journal of Health Economics and Management. RePEc:kap:ijhcfe:v:23:y:2023:i:1:d:10.1007_s10754-022-09337-6. Full description at Econpapers || Download paper |
| 2023 | Does health technology assessment compromise access to pharmaceuticals?. (2023). Stargardt, Tom ; Bussgen, Melanie. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:24:y:2023:i:3:d:10.1007_s10198-022-01484-4. Full description at Econpapers || Download paper |
Works by Katharina Elisabeth Blankart:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2021 | A Hard Look at “Soft” Cost?control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany In: CINCH Working Paper Series (since 2020). [Full Text][Citation analysis] | paper | 0 |
| 2011 | A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention In: Health Policy. [Full Text][Citation analysis] | article | 1 |
| 2012 | A systematic review of coverage decision-making on health technologies—Evidence from the real world In: Health Policy. [Full Text][Citation analysis] | article | 9 |
| 2013 | Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis In: Health Policy. [Full Text][Citation analysis] | article | 4 |
| 2016 | Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia In: Health Policy. [Full Text][Citation analysis] | article | 8 |
| 2016 | Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2016 | Dispensing behaviour of pharmacies in prescription drug markets In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| In: . [Full Text][Citation analysis] | article | 0 | |
| In: . [Full Text][Citation analysis] | article | 1 | |
| 2020 | Are patients more adherent to newer drugs? In: Health Care Management Science. [Full Text][Citation analysis] | article | 2 |
| In: . [Full Text][Citation analysis] | paper | 0 | |
| 2022 | The Effects of Off-label Drug Use on Disability and Medical Expenditure In: NBER Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2022 | The effects of off-label drug use on disability and medical expenditure.(2022) In: Ruhr Economic Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
| 2013 | Link between Process and Appraisal in Coverage Decisions In: Medical Decision Making. [Full Text][Citation analysis] | article | 0 |
| 2014 | Early Benefit Assessment of Pharmaceuticals in Germany In: Medical Decision Making. [Full Text][Citation analysis] | article | 4 |
| 2014 | Analysing coverage decision-making: opening Pandora’s box? In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 1 |
| 2016 | The diffusion of generics after patent expiry in Germany In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2018 | The impact of physician-level drug budgets on prescribing behavior In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2022 | Arzneimittel: Placebo bei Engpassbekämpfung In: Wirtschaftsdienst. [Full Text][Citation analysis] | article | 0 |
| 2021 | Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe In: REGION. [Full Text][Citation analysis] | article | 1 |
| 2020 | The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany In: Health Economics. [Full Text][Citation analysis] | article | 3 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 10 2023. Contact: CitEc Team